Research ExplorerPublicationsImplantation of paclitaxel-eluting stents in saphenous vein ...

Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study

Standard

Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. / Hoffmann, Rainer; Pohl, Tilmann; Köster, Ralf; Blindt, Ruediger; Boeckstegers, Peter; Heitzer, Thomas.

In: HEART, Vol. 93, No. 3, 03.2007, p. 331-334.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hoffmann, R, Pohl, T, Köster, R, Blindt, R, Boeckstegers, P & Heitzer, T 2007, 'Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study', HEART, vol. 93, no. 3, pp. 331-334. https://doi.org/10.1136/hrt.2006.094722

APA

Hoffmann, R., Pohl, T., Köster, R., Blindt, R., Boeckstegers, P., & Heitzer, T. (2007). Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. HEART, 93(3), 331-334. https://doi.org/10.1136/hrt.2006.094722

Vancouver

Hoffmann R, Pohl T, Köster R, Blindt R, Boeckstegers P, Heitzer T. Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. HEART. 2007 Mar;93(3):331-334. https://doi.org/10.1136/hrt.2006.094722

Bibtex

@article{55e3a73886724b5b9dfa9fa81af83a0c,
title = "Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study",
abstract = "OBJECTIVE: To define the clinical and angiographic follow-up results after implantation of paclitaxel-eluting stents (PESs) in stenotic saphenous vein grafts (SVGs).DESIGN: Prospective multicentre study. Comparison with a control group.METHODS: 60 consecutive patients with 65 lesions located in 65 SVGs (mean (SD) age of vein grafts 11.3 (5.7) years) treated with PES (V-Flex Plus, 2.7 microg/mm(2) paclitaxel, Cook) and 60 patients with 60 SVG lesions treated with bare metal stent (BMS) were included. Lesions had to be <20 mm in length and in grafts of 2.75-3.5 mm diameter. The 6 month angiographic follow-up was obtained on 51 lesions (79%) of the PES group and on 51 lesions (85%) of the BMS group.RESULTS: Baseline clinical and angiographic characteristics were comparable between both groups. At angiographic follow-up, three vein grafts in the PES group and five vein grafts in the BMS group were occluded. In-stent late lumen loss was lower in PES than in BMS (0.61 (0.81) vs 1.06 (0.72) mm, respectively; p = 0.021). In-stent binary restenosis rates were 12% vs 33%, respectively, (p = 0.012). Linear regression analysis showed BMS to be the only factor with an effect on late lumen loss (p = 0.011). Target-vessel failure rates were 18% in the PES group and 41% in the BMS group (p = 0.019), whereas major adverse cardiac event (MACE) rates at 180 days were 15% and 37%, respectively (p = 0.014).CONCLUSIONS: Implantation of non-polymer-based PES in SVG lesions is associated with a lower late lumen loss and restenosis rate than those of BMS. There remains a substantial target-vessel failure rate and MACE rate even at 6 months owing to graft occlusion or new lesions in the graft.",
keywords = "Aged, Case-Control Studies, Coronary Angiography, Coronary Restenosis/diagnostic imaging, Drug Implants, Female, Graft Occlusion, Vascular/diagnostic imaging, Humans, Immunosuppressive Agents/administration & dosage, Male, Middle Aged, Paclitaxel/administration & dosage, Prospective Studies, Saphenous Vein, Stents",
author = "Rainer Hoffmann and Tilmann Pohl and Ralf K{\"o}ster and Ruediger Blindt and Peter Boeckstegers and Thomas Heitzer",
year = "2007",
month = mar,
doi = "10.1136/hrt.2006.094722",
language = "English",
volume = "93",
pages = "331--334",
journal = "HEART",
issn = "1355-6037",
publisher = "BMJ PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study

AU - Hoffmann, Rainer

AU - Pohl, Tilmann

AU - Köster, Ralf

AU - Blindt, Ruediger

AU - Boeckstegers, Peter

AU - Heitzer, Thomas

PY - 2007/3

Y1 - 2007/3

N2 - OBJECTIVE: To define the clinical and angiographic follow-up results after implantation of paclitaxel-eluting stents (PESs) in stenotic saphenous vein grafts (SVGs).DESIGN: Prospective multicentre study. Comparison with a control group.METHODS: 60 consecutive patients with 65 lesions located in 65 SVGs (mean (SD) age of vein grafts 11.3 (5.7) years) treated with PES (V-Flex Plus, 2.7 microg/mm(2) paclitaxel, Cook) and 60 patients with 60 SVG lesions treated with bare metal stent (BMS) were included. Lesions had to be <20 mm in length and in grafts of 2.75-3.5 mm diameter. The 6 month angiographic follow-up was obtained on 51 lesions (79%) of the PES group and on 51 lesions (85%) of the BMS group.RESULTS: Baseline clinical and angiographic characteristics were comparable between both groups. At angiographic follow-up, three vein grafts in the PES group and five vein grafts in the BMS group were occluded. In-stent late lumen loss was lower in PES than in BMS (0.61 (0.81) vs 1.06 (0.72) mm, respectively; p = 0.021). In-stent binary restenosis rates were 12% vs 33%, respectively, (p = 0.012). Linear regression analysis showed BMS to be the only factor with an effect on late lumen loss (p = 0.011). Target-vessel failure rates were 18% in the PES group and 41% in the BMS group (p = 0.019), whereas major adverse cardiac event (MACE) rates at 180 days were 15% and 37%, respectively (p = 0.014).CONCLUSIONS: Implantation of non-polymer-based PES in SVG lesions is associated with a lower late lumen loss and restenosis rate than those of BMS. There remains a substantial target-vessel failure rate and MACE rate even at 6 months owing to graft occlusion or new lesions in the graft.

AB - OBJECTIVE: To define the clinical and angiographic follow-up results after implantation of paclitaxel-eluting stents (PESs) in stenotic saphenous vein grafts (SVGs).DESIGN: Prospective multicentre study. Comparison with a control group.METHODS: 60 consecutive patients with 65 lesions located in 65 SVGs (mean (SD) age of vein grafts 11.3 (5.7) years) treated with PES (V-Flex Plus, 2.7 microg/mm(2) paclitaxel, Cook) and 60 patients with 60 SVG lesions treated with bare metal stent (BMS) were included. Lesions had to be <20 mm in length and in grafts of 2.75-3.5 mm diameter. The 6 month angiographic follow-up was obtained on 51 lesions (79%) of the PES group and on 51 lesions (85%) of the BMS group.RESULTS: Baseline clinical and angiographic characteristics were comparable between both groups. At angiographic follow-up, three vein grafts in the PES group and five vein grafts in the BMS group were occluded. In-stent late lumen loss was lower in PES than in BMS (0.61 (0.81) vs 1.06 (0.72) mm, respectively; p = 0.021). In-stent binary restenosis rates were 12% vs 33%, respectively, (p = 0.012). Linear regression analysis showed BMS to be the only factor with an effect on late lumen loss (p = 0.011). Target-vessel failure rates were 18% in the PES group and 41% in the BMS group (p = 0.019), whereas major adverse cardiac event (MACE) rates at 180 days were 15% and 37%, respectively (p = 0.014).CONCLUSIONS: Implantation of non-polymer-based PES in SVG lesions is associated with a lower late lumen loss and restenosis rate than those of BMS. There remains a substantial target-vessel failure rate and MACE rate even at 6 months owing to graft occlusion or new lesions in the graft.

KW - Aged

KW - Case-Control Studies

KW - Coronary Angiography

KW - Coronary Restenosis/diagnostic imaging

KW - Drug Implants

KW - Female

KW - Graft Occlusion, Vascular/diagnostic imaging

KW - Humans

KW - Immunosuppressive Agents/administration & dosage

KW - Male

KW - Middle Aged

KW - Paclitaxel/administration & dosage

KW - Prospective Studies

KW - Saphenous Vein

KW - Stents

U2 - 10.1136/hrt.2006.094722

DO - 10.1136/hrt.2006.094722

M3 - SCORING: Journal article

C2 - 16940392

VL - 93

SP - 331

EP - 334

JO - HEART

JF - HEART

SN - 1355-6037

IS - 3

ER -